1-fluoro-2-methoxy-4-propylbenzene | 1195931-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-fluoro-2-methoxy-4-propylbenzene
• CAS: 1195931-57-7
• 化学式: C₁₀H₁₃FO
• 分子量: 168.211
• InChiKey: XPCGOJGKRUAYSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-甲氧基-4-丙基苯基三氟甲磺酸酯 在 [COD(Pd-AlPhos)₂] 、 cesium fluoride 作用下， 以 环己烷 为溶剂， 反应 24.0h， 以96%的产率得到1-fluoro-2-methoxy-4-propylbenzene
  参考文献：
  名称：

  A Fluorinated Ligand Enables Room-Temperature and Regioselective Pd-Catalyzed Fluorination of Aryl Triflates and Bromides

  摘要：

  A new biaryl monophosphine ligand (AlPhos, L1) allows for the room-temperature Pd-catalyzed fluorination of a variety of activated (hetero)aryl trifiates. Furthermore, aryl triflates and bromides that are prone to give mixtures of regioisomeric aryl fluorides with Pd-catalysis can now be converted to the desired aryl fluorides with high regioselectivity. Analysis of the solid-state structures of several Pd(II) complexes, as well as density functional theory (DFT) calculations, shed light on the origin of the enhanced reactivity observed with L1.

  DOI：

  10.1021/jacs.5b09308

文献信息

• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR GPR120 ET LEURS UTILISATIONS
  申请人：METABOLEX INC

  公开号：WO2011159297A1

  公开（公告）日：2011-12-22

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。
• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DE RÉCEPTEURS GPR 120 ET LEURS APPLICATIONS
  申请人：METABOLEX INC

  公开号：WO2010080537A1

  公开（公告）日：2010-07-15

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。
• GPR120 RECEPTOR AGONISTS AND USES THEREOF
  申请人：Shi Dong Fang

  公开号：US20110313003A1

  公开（公告）日：2011-12-22

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  提供了GPR120激动剂。这些化合物对于治疗代谢性疾病非常有用，包括II型糖尿病和与血糖控制不佳有关的疾病。
• Formation of ArF from LPdAr(F): Catalytic Conversion of Aryl Triflates to Aryl Fluorides
  作者：Donald A. Watson、Mingjuan Su、Georgiy Teverovskiy、Yong Zhang、Jorge García-Fortanet、Tom Kinzel、Stephen L. Buchwald

  DOI：10.1126/science.1178239

  日期：2009.9.25

  currently in use is of great interest. We have prepared [LPd(II)Ar(F)] complexes, where L is a biaryl monophosphine ligand and Ar is an aryl group, and identified conditions under which reductive elimination occurs to form an Ar-F bond. On the basis of these results, we have developed a catalytic process that converts aryl bromides and aryl triflates into the corresponding fluorinated arenes by using simple

  容易氟化 氟原子已成为药物中有用的取代基。然而，合成引入它们仍然具有挑战性，因为目前形成碳氟键的方法需要腐蚀性条件或有些奇特的、因此昂贵的试剂。一个症结是传统钯催化剂未能将芳基与配位氟化物偶联。沃森等人。（第 1661 页，8 月 13 日在线发表；参见 Gouverneur 的 Perspective）表明，将钯与精心设计的膦配体配对可使用简单的氟化物盐产生用于芳基氟化的多功能催化剂。该方法可耐受一系列官能团，并应促进多种含氟芳烃目标的有效合成。催化剂能够使用简单的氟化物盐形成多功能的碳氟键。尽管药物重要性日益增加，但氟化芳族有机分子仍然难以合成。目前的方法需要苛刻的反应条件或高度专业化的试剂，使得复杂氟芳烃的制备具有挑战性。因此，开发克服目前使用的这些技术的局限性的通用制备方法是非常有意义的。我们制备了 [LPd(II)Ar(F)] 配合物，其中 L 是联芳单膦配体，Ar 是芳基，并确定了发生还原消除以形成
• NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS
  申请人：Riguet Eric

  公开号：US20100004246A1

  公开（公告）日：2010-01-07

  The present invention provides novel compounds of formula I wherein W 1 , W 2 , W 3 , W 4 , W 5 , B, X 1 , X 2 , X 3 , X 4 , X 5 , E and L are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype B (“GABA B ”) positive allosteric modulators (enhancers), which are useful to provide methods of treating or preventing diseases or disorders, including treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, panic disorder, posttraumatic stress disorders, urge urinary incontinence, gastroesophageal reflux disease, transient lower oesophageal sphincter relaxations, functional gastrointestinal disorders and irritable bowel syndrome.

  本发明提供了式I的新化合物，其中W1、W2、W3、W4、W5、B、X1、X2、X3、X4、X5、E和L的定义如本文所述；发明的化合物是γ-氨基丁酸受体亚型B（“GABAB”）正向变构调节剂（增强剂），可用于提供治疗或预防疾病或疾病的方法，包括焦虑、抑郁、癫痫、精神分裂症、认知障碍、痉挛和骨骼肌肌紧张、脊髓损伤、多发性硬化、肌萎缩性侧索硬化、脑瘫、神经痛和与可卡因和尼古丁相关的渴望、惊恐障碍、创伤后应激障碍、急迫性尿失禁、胃食管反流病、暂时性下食管括约肌松弛、功能性胃肠疾病和肠易激综合征的治疗。